Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food allergens. And we built our inspiration into our name—Alladapt.
Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens.
Food allergy is a serious disease, with potentially life-threatening consequences. The disease has grown dramatically in recent years and now affects more than 6 million children¹ and 26 million adults² in the United States alone. Importantly, about half of people with food allergy are reactive to multiple foods, which further increases the risk of anaphylaxis due to accidental ingestion.
The chronic, unpredictable components of this disease can elevate anxiety in patients and their families, and place extreme limitations on their lives. It is our goal to help patients experience more of life’s magical moments with less fear and greater confidence.
¹ Gupta, R. S., Warren, C. M., Smith, B. M., Blumenstock, J. A., Jiang, J., Davis, M. M., et al. (2018). "The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States." Pediatrics 142(6).
² Gupta, R. S., Warren, C. M., Smith, B. M., Jiang, J., Blumenstock, J. A., Davis, M. M., et al. (2019). "Prevalence and Severity of Food Allergies Among US Adults." JAMA Netw Open 2(1): e185630.
ADP101, our lead drug candidate, is being developed for the mitigation of food allergy provoked by either single or multiple proteins from a wide-ranging set of foods. We are working to formulate this proprietary oral immunotherapy drug candidate as a single agent capable of delivering highly-consistent, well-characterized, precisely-dosed protein from the vast majority of commonly allergenic protein families. ADP101 is based on an intellectual property estate that includes patents and accompanying clinical data licensed from Stanford University.
--Ashley to consider adding list of presentations and publications--
Since 20XX, many publications have focused on food allergy as a single disease...
-- List of presentations and publications --
We bring an unwavering commitment to collaborating with patients, family members and physicians so that the values and needs of stakeholders in the food allergy community can be incorporated into our program. Our foundational research was originally inspired by insights shared with us by patients and families who were frustrated by the absence of adequate treatment options for such a serious disease. Our outreach revealed:
These insights, and the voices of patients, are at the heart of everything we do at Alladapt.
In an effort to support food allergy advocacy and advance a broader understanding of this serious and complex disease, we have compiled the following links. Whether you are a patient, a family member, or someone seeking a better understanding of this disease, these resources may be useful. Please note these links will take you away from the Alladapt website to sites that are maintained by independent groups.
Dr. Dombkowski co-founded Alladapt Immunotherapeutics with Dr. Kari Nadeau. She was previously the CEO and Co-founder of Before Brands, a company she also co-founded with Dr. Nadeau. At Before Brands, Dr. Dombkowski led the company from inception through initial product launch, culminating in a global commercial partnership with Nestle Health Science. She has more than 20 years of experience as an operating executive, entrepreneur and investor. Prior operating roles include serving as Chief Business Officer and Vice President of Operations for consumer genomics company 23andMe, where she also served as a member of the company’s Board of Directors. In addition, she spent nearly 15 years as a Managing Director at health care venture capital firms Bay City Capital and MPM Capital. Her portfolio of innovative biotechnology, medical device, consumer health and HCIT companies has included 23andMe, Adolor, Alnara, Before Brands, BioVitrum, Epizyme, iPierian, Neosil, Nevro, Rigel, Tercica and Twist. Earlier in her career, she was an equity analyst for Tiger Management LLC and for Dresdner RCM Global Investors.
Dr. Dombkowski holds a PhD in Mathematics from Rice University and received her BA in Mathematics from Wellesley College.
Dr. McClintock has served as Alladapt’s Chief Medical Officer since 2018. Prior to joining Alladapt, Dr. McClintock was Global Head of Innovation for Immunology, Infectious Disease and Ophthalmology at Genentech/Roche. Her responsibilities included accelerating use of emergent technologies and enabling novel approaches to clinical development with a focus on pediatrics. Prior to this role, Dr. McClintock, held roles of increasing responsibility at Genentech/Roche, including Global Head of Pipeline and Portfolio planning for Immunology, Infectious Disease and Ophthalmology as well as Interim Global Co-Head of Ophthalmology. Earlier in Dr. McClintock’s career, she was deeply involved in both immunology and ophthalmology clinical development across a range of phases, from IND-enabling work and early clinical trials through post-marketing commitments and medical affairs activities. Dr. McClintock was involved in key clinical development activities for omalizumab (Xolair) and ranibizumab (Lucentis) as well as other pipeline molecules.
Dr. McClintock received a BA in Chemistry from Duke University and an MD from the University of Virginia. Dr. McClintock completed her training in Internal Medicine and Pulmonary and Critical Care Medicine, both at the University of California, San Francisco.
Dr. Kirchner joined Alladapt in early 2019 as Vice President of CMC where he oversees all aspects of the Manufacturing, Formulation, and Chemistry Manufacturing and Control (CMC) programs, including technical analytics. He has over 25 years of experience in the pharmaceutical field. Dr. Kirchner has held leadership positions in organizations focused on CMC development. He has built technical operations teams from Phase 1 through commercial launch, encompassing analytical, process and formulation development as well as drug substance and drug product manufacturing. Dr. Kirchner’s career has included developing duplex oligonucleotide therapeutics at Corgentech, capsaicin at Anesiva, ergot alkaloids at MAP Pharmaceuticals and, most recently, an aminogycoside at Achaogen.
Dr. Kirchner received his PhD in Chemistry from the University of Washington.
Dr. Lal joined Alladapt in 2018 to lead critical aspects of the company’s protein biochemistry research, to drive clinical biomarker development, and to manage bioinformatics and data science activities. Prior to Alladapt, she worked at several leading-edge companies: Roche Sequencing where she worked in oncology bioinformatics, Gilead Sciences where she focused on clinical biomarkers and companion diagnostics across a range of therapeutic indications, Genentech where she led biomarker development work with notable focus on atopic diseases such as asthma and on autoimmune diseases, and XDx where she developed the statistical algorithm “AlloMap” containing multiple genes approved under IVDMIA guidance by FDA as an aid in diagnostics for heart transplant. Following her PhD, she spent seven years at Incyte Genomics where she managed a bioinformatics group involved with data mining and usage of novel methods for the discovery of secreted proteins and the analysis of laboratory data from cell-based assays.
Dr. Lal has a PhD in Immunology from the Medical University of South Carolina.
Ms. Milani joined the Alladapt team in March 2019 as Vice President of Supply Chain Operations, overseeing planning, raw material procurement, contract manufacturing operations management, finished goods packaging, logistics and distribution. Since joining, Amelia has played a critical role in establishing our Clinical Supply Chain in preparation for Alladapt’s first IND filing and trial. Prior to joining Alladapt, Amelia was Senior Director of Manufacturing & Supply Chain, Clinical & Commercial, at Achaogen, a company focused on novel anti-infectives. She also worked at Roche in Basel, Switzerland where she was part of the Commercial Supply Chain organization and was at Genentech from 2007 to 2012 holding various Supply Chain roles of increasing responsibility.
Ms. Milani holds a BS in Economics & Finance from the University of Arizona and an MBA with emphasis in Supply Chain Management from Arizona State University.
Ms. Sullivan joined Alladapt as Vice President of Clinical Operations in 2018, and her role was expanded to oversee Development Operations in 2019. She has held leadership positions at companies including BioMarin Pharmaceuticals, Roche and Genentech, and spent several years as Director of Clinical Research for a large HIV practice in San Francisco. Prior to joining Alladapt, Ms. Sullivan’s biotech career included increasingly responsible roles at Roche Genentech that involved end-to-end management of early through post-commercial stage clinical trials. Most recently, she was a Clinical Program Group Leader across the Immunology, Ophthalmology and Neuroscience portfolio with Genentech's Research and Early Development (gRED) unit. Prior to her time at Roche Genentech, she was at BioMarin Pharmaceuticals where she contributed to the BLA filing for BioMarin's first marketed product, Aldurazyme for mucopolysaccharidosis type I.
Ms. Sullivan received a BA in Biological Sciences from the University of California, Santa Barbara.
Mr. Reddy is the Director of Finance at Alladapt and leads all financial operations including accounting, planning, budgeting and reporting. Sid joined Alladapt from Adamas Pharmaceuticals, a commercial-stage pharmaceutical company, where he played a critical role on the finance team that helped launch Adamas’ first drug and that oversaw the accounting for a range of public and private equity rounds, debt financing, and royalty financing. Prior to joining Adamas, Sid worked at Calithera Biosciences, a clinical-stage biopharmaceutical company. Sid began his career with PricewaterhouseCoopers and Ernst & Young where he audited and consulted with both publicly traded and privately held companies in the life sciences industry.
Mr. Reddy is a CPA in the State of California and received his MS/MBA from Northeastern University.